As Hostile Takeover Clock Ticks, Mylan Vows ‘Love’ For Perrigo Majority Stake
This article was originally published in The Tan Sheet
Analysts leave a Mylan briefing still doubting the firm’s reasons for attempting to acquire Dublin-based Perrigo and ascertaining nothing new from Mylan executives’ comments. Chairman Robert Coury says with only a majority stake, Mylan gains by not giving up 2.3 shares for the non-tendered Perrigo shares.
You may also be interested in...
“I don’t know if there’s a misconception that a different set of adverting rules apply to social media," says FTC attorney Christine DeLorme during FDLI conference. The FTC also sees "a lot of attempts at disclaimers. They might say, ‘Of course there’s no cure for COVID, but...’"
Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.
DuPont says it and P&G “have conducted extensive research on human commensals bacteria to help address metabolic health issues in humans.” The partnership "will help us further advance our probiotic innovation via a next generation solution that will prove beneficial to the health and well-being of consumers around the world,” says Paul Gama, P&G personal health care president.